Macrophage Activation Syndrome

Introduction

Potentially fatal complication of rheumatic diseases.
Characterized by excessive activation and expansion of macrophages and T lymphocytes.
Classified as secondary or reactive hemophagocytic lymphohistiocytosis.
Produces overwhelming systemic inflammatory reaction resembling disseminated intravascular coagulation.

Occurs most frequently in systemic juvenile idiopathic arthritis.
Complicates 7 to 13 percent of systemic juvenile idiopathic arthritis cases overtly.
Subclinical disease present in up to 30 percent of active systemic juvenile idiopathic arthritis patients.
Affects 1 to 9 percent of pediatric systemic lupus erythematosus patients.
Implicated triggers include primary rheumatic disease flares, viral infections including Epstein-Barr virus and cytomegalovirus, bacterial infections, and drug modifications.

Marked by profound depression of natural killer cell and cytotoxic T lymphocyte function.
Abnormal perforin expression prevents clearance of infected cells.
Persistent antigenic stimulation drives massive expansion of T cells and macrophages.
Escalating pro-inflammatory cytokines generate massive cytokine storm.
Elevated interleukin-18 drives pathogenic interferon-gamma production.
Hemophagocytic macrophages overexpress surface marker cluster of differentiation 163.
Macrophages aggressively consume hemoglobin-haptoglobin complexes, releasing free iron.
Ferritin excessively sequesters free iron, driving extreme hyperferritinemia.

Disease course dramatic and rapidly evolving.
Unremitting, continuous high fever replaces typical quotidian spiking fever of active arthritis.
Profound hepatomegaly, splenomegaly, and generalized lymphadenopathy.
Hemorrhagic manifestations include petechiae, widespread ecchymoses, epistaxis, and gastrointestinal bleeding.
Central nervous system involvement produces mental status changes, lethargy, seizures, and coma.
Rapid progression to multiorgan failure, acute respiratory distress syndrome, and shock.

Precipitous fall in multiple blood cell lines including leukopenia, anemia, and thrombocytopenia.
Platelet count drop typically occurs earliest.
Paradoxical drop in erythrocyte sedimentation rate alongside persistently high C-reactive protein.
Sedimentation rate drop driven by profound hypofibrinogenemia.
Extreme hyperferritinemia, often exceeding 10,000 nanograms per milliliter.
Glycosylated ferritin fraction classically falls below 20 percent.
Coagulopathy features prolonged prothrombin time, elevated D-dimers, and consumption of clotting factors.
Hepatic dysfunction produces highly elevated transaminases, elevated bilirubin, and raised lactate dehydrogenase.
Elevated serum triglycerides and severe hyponatremia common.
Bone marrow aspirates demonstrate pronounced hemophagocytosis by activated macrophages.

A patient with known or suspected Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as having MAS if the following criteria are met:

Parameter	Threshold Value
Ferritin	> 684 ng/mL
Platelet Count	≤ 181 x 10⁹/L
Aspartate Aminotransferase (AST)	> 48 U/L
Triglycerides	> 156 mg/dL (or 1.76 mmol/L)
Fibrinogen	≤ 360 mg/dL

Dynamic Nature: MAS is a rapidly evolving syndrome. A downward trend in cell counts (even if they remain within "normal" ranges) or a sudden, massive spike in ferritin is often more clinically significant than a single static value.
HLH 2004 Criteria:While the above is specific to sJIA, the broader HLH-2004 criteria (requiring 5 out of 8 markers including splenomegaly, cytopenias, and low NK cell activity) are also frequently used for secondary MAS in other autoimmune contexts.
Bone Marrow: Hemophagocytosis in the bone marrow is characteristic but is not required for diagnosis, as it may be absent in the early stages.

Distinguishing macrophage activation from primary disease flare remains critical.
Flare features spiking fever, increased platelet counts, increased fibrinogen, and highly elevated erythrocyte sedimentation rate.
Must exclude severe sepsis, malignancy-associated hemophagocytosis, and drug reactions.
Reye syndrome shares hepatic encephalopathy but lacks characteristic cytopenias.
Thrombotic thrombocytopenic purpura features microangiopathic anemia absent in typical macrophage activation.

High mortality mandates immediate therapeutic intervention upon recognition.
Intravenous methylprednisolone pulse therapy serves as first-line treatment.
- Administered at 30 milligrams per kilogram for 3 consecutive days.
- Transition to oral prednisolone taper at 2 to 3 milligrams per kilogram daily.
Cyclosporine A added at 2 to 7 milligrams per kilogram daily if steroid response proves unsatisfactory within 24 to 48 hours.
Tacrolimus serves as effective alternative calcineurin inhibitor.
Refractory disease warrants 2004 hemophagocytic lymphohistiocytosis treatment protocol utilizing Etoposide.
- Etoposide carries severe myelosuppression and hepatic toxicity risks.
Antithymocyte globulin offers safer alternative for patients with hepatic or renal impairment.
Anakinra, an interleukin-1 receptor antagonist, effectively extinguishes underlying cytokine storms.
Rituximab targets B lymphocytes, proving highly effective for Epstein-Barr virus triggered disease.

Mortality rates historically approach 20 percent.
Increasing awareness, earlier diagnosis, and aggressive targeted therapies progressively improve overall outcomes.